• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

    13.41 +0.11 (+0.83%)
    Streaming Delayed Price Updated: 10:17 AM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 81,941
    Open 13.45
    Bid (Size) 13.39 (200)
    Ask (Size) 13.44 (100)
    Prev. Close 13.30
    Today's Range 13.40 - 14.19
    52wk Range 3.105 - 17.25
    Shares Outstanding 55,945,551
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Which stocks are moving on Wednesday? ↗
    Via Chartmill
    News headline image
    Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
    From Design Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +47.4%
    +47.4%
    1 Month
    +19.4%
    +19.4%
    3 Month
    +28.8%
    +28.8%
    6 Month
    +104.7%
    +104.7%
    1 Year
    +188.4%
    +188.4%

    More News

    Read More
    News headline image
    Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in Upcoming Investor Conferences
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in Upcoming Investor Conferences
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday ↗
    Via Benzinga
    News headline image
    Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Appoints Justin Gover to Board of Directors
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller ↗
    Via Benzinga
    News headline image
    Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
    From Bright Peak Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Top movers in Friday's pre-market session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Design Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Design Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Design Therapeutics, Inc. - Common Stock trade on?
    Design Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Design Therapeutics, Inc. - Common Stock?
    The ticker symbol for Design Therapeutics, Inc. - Common Stock is DSGN on the Nasdaq Stock Market
    What is the current price of Design Therapeutics, Inc. - Common Stock?
    The current price of Design Therapeutics, Inc. - Common Stock is 13.41
    When was Design Therapeutics, Inc. - Common Stock last traded?
    The last trade of Design Therapeutics, Inc. - Common Stock was at 05/04/26 10:17 AM ET
    What is the market capitalization of Design Therapeutics, Inc. - Common Stock?
    The market capitalization of Design Therapeutics, Inc. - Common Stock is 750.23M
    How many shares of Design Therapeutics, Inc. - Common Stock are outstanding?
    Design Therapeutics, Inc. - Common Stock has 750M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.